linagliptin and semaglutide together We are pleased to announce the launch of GLIPIQⓇ (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM), setting a new benchmark in affordability for GLP-1 therapy expanding New GLP-1 Guidelines for Type

With the growing number of people taking these medications and the gradually lengthening amount of time over which we have now been able to observe the unintended effects that these agents may have, it is not altogether surprising that side effects of these medications in athletes are beginning to appear

Experimental models of impaired insulin signaling in podocytes led to DN-like kidney damage

Without a calculator, working out dosing can be error-prone

And their side effect profiles, based on available data, appear milder

no clear or consistent patterns or significant effects were found (see Additional file 1)

It often occurs as the body adjusts to the slowed gastric emptying that tirzepatide causes